Arnt V Kristen

List of Publications by Year
in descending order

110 papers	9,390 citations	57758 44 h-index	39675 94 g-index
118 all docs	118 docs citations	118 times ranked	7122 citing authors

#	Article	IF	Citations
1	Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 11-21.	27.0	1,944
2	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	27.0	1,558
3	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
4	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	2.8	338
5	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation, 2019, 139, 431-443.	1.6	319
6	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	3.9	312
7	Longitudinal Left Ventricular Function for Prediction of Survival in Systemic Light-Chain Amyloidosis. Journal of the American College of Cardiology, 2012, 60, 1067-1076.	2.8	253
8	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	2.1	230
9	Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm, 2008, 5, 235-240.	0.7	214
10	Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegenerative Disease Management, 2019, 9, 5-23.	2.2	168
11	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	7.1	153
12	Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clinical Research in Cardiology, 2012, 101, 805-813.	3.3	121
13	In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain, 2015, 138, 549-562.	7.6	112
14	Non-invasive predictors of survival in cardiac amyloidosis. European Journal of Heart Failure, 2007, 9, 617-624.	7.1	109
15	Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood, 2010, 116, 2455-2461.	1.4	109
16	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	1.7	107
17	Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal, 2022, 43, 391-400.	2.2	105
18	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	2.1	97

#	Article	IF	Citations
19	Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?. Clinical Research in Cardiology, 2019, 108, 1324-1330.	3.3	93
20	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	10.2	93
21	Cardiac Amyloid Load. Journal of the American College of Cardiology, 2016, 68, 13-24.	2.8	76
22	High prevalence of amyloid in 150 surgically removed heart valvesâ€"a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovascular Pathology, 2010, 19, 228-235.	1.6	75
23	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	1.7	70
24	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis. JAMA Cardiology, 2019, 4, 466.	6.1	68
25	Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. Journal of Heart and Lung Transplantation, 2018, 37, 611-618.	0.6	66
26	High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. British Journal of Haematology, 2004, 127, 543-551.	2.5	62
27	Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart, 2016, 3, e000289.	2.3	62
28	Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Design, Development and Therapy, 2015, 9, 6319.	4.3	61
29	Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2015, 8, 117-127.	2.4	61
30	Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosisâ˜†. European Journal of Cardio-thoracic Surgery, 2008, 33, 257-262.	1.4	60
31	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
32	MR-Relaxometry of Myocardial Tissue. Investigative Radiology, 2007, 42, 636-642.	6.2	57
33	Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy, 2020, 34, 357-370.	2.6	55
34	Noninvasive Risk Stratification of Patients With Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 502-510.	5.3	54
35	Rapid Progression of Left Ventricular Wall Thickness Predicts Mortality in Cardiac Light-chain Amyloidosis. Journal of Heart and Lung Transplantation, 2007, 26, 1313-1319.	0.6	52
36	Amyloid in endomyocardial biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 523-532.	2.8	50

#	Article	IF	Citations
37	Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clinical Research in Cardiology, 2018, 107, 158-169.	3.3	50
38	Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis â€“ Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). PLoS ONE, 2017, 12, e0173086.	2.5	50
39	Asymptomatic Sustained Ventricular Fibrillation in a Patient With Left Ventricular Assist Device. Annals of Emergency Medicine, 2011, 57, 25-28.	0.6	49
40	Early data on longâ€term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2â€year update from the openâ€label extension of the NEUROâ€TTR trial. European Journal of Neurology, 2020, 27, 1374-1381.	3.3	49
41	Sural nerve injury in familial amyloid polyneuropathy. Neurology, 2017, 89, 475-484.	1.1	48
42	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	2.6	48
43	Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 187-195.	3.0	47
44	Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 153-162.	3.0	47
45	Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 196-204.	3.0	46
46	Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac lightâ€chain amyloidosis. European Journal of Heart Failure, 2009, 11, 1014-1020.	7.1	45
47	Fast assessment of long axis strain with standard cardiovascular magnetic resonance: a validation study of a novel parameter with reference values. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 69.	3.3	45
48	MALDI Mass Spectrometry Imaging: A Novel Tool for the Identification and Classification of Amyloidosis. Proteomics, 2017, 17, 1700236.	2.2	44
49	Acupuncture improves exercise tolerance of patients with heart failure: a placebo-controlled pilot study. Heart, 2010, 96, 1396-1400.	2.9	42
50	Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.6	41
51	Prevalence of Germline Mutations in the TTR Gene in a Consecutive Series of Surgical Pathology Specimens With ATTR Amyloid. American Journal of Surgical Pathology, 2009, 33, 58-65.	3.7	39
52	Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica, 2017, 102, 1424-1431.	3.5	39
53	Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis, 2007, 28, 2053-2064.	2.4	37
54	Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. International Journal of Cardiology, 2013, 164, 179-184.	1.7	37

#	Article	IF	Citations
55	Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clinical Research in Cardiology, 2015, 104, 640-647.	3.3	36
56	Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Journal of Neurology, 2020, 267, 703-712.	3.6	35
57	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	2.1	34
58	Myocardial contraction fraction derived from cardiovascular magnetic resonance cine imagesâ€"reference values and performance in patients with heart failure and left ventricular hypertrophy. European Heart Journal Cardiovascular Imaging, 2017, 18, 1414-1422.	1.2	32
59	Endothelin-1 inhibits the neuronal norepinephrine transporter in hearts of male rats. Cardiovascular Research, 2005, 67, 283-290.	3.8	29
60	Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica, 2019, 104, 1451-1459.	3.5	29
61	Heart Rate Reduction for 12 Months With Ivabradine Reduces Left Ventricular Mass in Cardiac Allograft Recipients. Transplantation, 2009, 88, 835-841.	1.0	28
62	Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 132-133.	3.0	26
63	Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis. Journal of Cardiovascular Magnetic Resonance, 2019, 21, 53.	3.3	25
64	Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients. Transplant International, 2008, 21, 963-971.	1.6	24
65	Risk Stratification in Cardiac Amyloidosis: Novel Approaches. Transplantation, 2005, 80, S151-S155.	1.0	23
66	Return to Work After Heart Transplantation: Discrepancy With Subjective Work Ability. Transplantation, 2009, 87, 1001-1005.	1.0	22
67	Inhibition of apoptosis by the intrinsic but not the extrinsic apoptotic pathway in myocardial ischemia-reperfusion. Cardiovascular Pathology, 2013, 22, 280-286.	1.6	22
68	Preserved Norepinephrine Reuptake but Reduced Sympathetic Nerve Endings in Hypertrophic Volume-Overloaded Rat Hearts. Journal of Cardiac Failure, 2006, 12, 577-583.	1.7	20
69	Suspected cardiac amyloidosis: Endomyocardial biopsy remains the diagnostic gold-standard. American Journal of Hematology, 2007, 82, 328-328.	4.1	19
70	Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 132-141.	3.0	19
71	Indications for High-Dose Chemotherapy with Autologous Stem Cell Support in Patients with Systemic Amyloid Light Chain Amyloidosis. Transplantation, 2005, 80, S160-S163.	1.0	18
72	Effects of protein A immunoadsorption in patients with chronic dilated cardiomyopathy. Journal of Clinical Apheresis, 2010, 25, 315-322.	1.3	17

#	Article	IF	Citations
73	Indications for Liver Transplantation in Patients with Amyloidosis: A Single-Center Experience with 11 Cases. Transplantation, 2005, 80, S156-S159.	1.0	16
74	Peak Vâ€™O₂ is an independent predictor of survival in patients with cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 167-173.	3.0	16
75	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	2.6	16
76	Transthyretin valine-94-alanine, a novel variant associated with late-onset systemic amyloidosis with cardiac involvement. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 283-287.	3.0	15
77	Negative pretransplant serostatus forToxoplasma gondiiis associated with impaired survival after heart transplantation. Transplant International, 2010, 23, 382-389.	1.6	15
78	Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 202-210.	3.0	15
79	Prognostic significance of semiautomatic quantification of left ventricular long axis shortening in systemic light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 45-53.	3.0	15
80	Right ventricular long axis strainâ€"validation of a novel parameter in non-ischemic dilated cardiomyopathy using standard cardiac magnetic resonance imaging. European Journal of Radiology, 2016, 85, 1322-1328.	2.6	15
81	Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clinical Research in Cardiology, 2006, 95, 671-674.	3.3	14
82	The â€œWagshurst studyâ€: p.Val40Ile transthyretin gene variant causes late-onset cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 267-275.	3.0	11
83	Anterior Aortic Plane Systolic Excursion: A Novel Indicator of Transplant-Free Survival in Systemic Light-Chain Amyloidosis. Journal of the American Society of Echocardiography, 2016, 29, 1188-1196.	2.8	11
84	Amyloid cardiomyopathy. Herz, 2020, 45, 267-271.	1.1	10
85	Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 91-99.	3.0	8
86	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	1.7	8
87	Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms. Vascular Health and Risk Management, 2021, Volume 17, 661-673.	2.3	8
88	Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor. Clinical Research in Cardiology, 2015, 104, 250-257.	3.3	7
89	Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 175-183.	3.0	7
90	Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Cardiology and Therapy, 2022, 11, 393-405.	2.6	7

#	Article	IF	Citations
91	Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. International Journal of Cardiology, 2014, 176, 1113-1115.	1.7	6
92	Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy. Journal of Cardiac Failure, 2019, 25, S9-S10.	1.7	3
93	Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis. Clinical Research in Cardiology, 2021, 110, 579-590.	3.3	3
94	Interventional treatment of the left subclavian in 2 patients with coronary steal syndrome. World Journal of Cardiology, 2017, 9, 65.	1.5	3
95	Reply. Journal of the American College of Cardiology, 2016, 68, 2494-2495.	2.8	2
96	Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis. World Journal of Cardiology, 2021, 13, 55-67.	1.5	2
97	Temporal Trends of Wild-type Attr Amyloidosis in the Transthyretin Amyloidosis Outcomes Survey. Journal of Cardiac Failure, 2020, 26, S82.	1.7	2
98	Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis. Blood, 2015, 126, 1790-1790.	1.4	2
99	Respiratory muscle weakness and inefficient ventilation in heart failure due to light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 129-136.	3.0	1
100	Skeletal scintigraphy in patients with transthyretin-related amyloidosis. International Journal of Cardiology, 2014, 171, e16-e17.	1.7	1
101	RISK STRATIFICATION IN WILD-TYPE TRANSTHYRETIN AMYLOIDOSIS. Journal of the American College of Cardiology, 2016, 67, 1543.	2.8	1
102	Diagnosis of cardiac involvement in systemic amyloidosis by state-of-the-art echocardiography: where are we now?. Expert Opinion on Orphan Drugs, 2016, 4, 639-648.	0.8	1
103	Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis. World Journal of Cardiology, 2021, 13, 55-67.	1.5	1
104	Prospective Phase II Study Using Dexamethasone Induction Therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation in 30 Patients with Systemic AL Amyloidosis.. Blood, 2009, 114, 3401-3401.	1.4	1
105	Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex). Blood, 2013, 122, 1993-1993.	1.4	1
106	COMPARISON OF LATE GADOLINIUM ENHANCEMENT PATTERNS IN DIFFERENT FORMS OF CARDIAC AMYLOIDOSIS. Journal of the American College of Cardiology, 2013, 61, E937.	2.8	0
107	Differences in Transthyretin Amyloidosis between the United States and the Rest of the World: A Report from the Transthyretin Amyloid Outcome Survey (THAOS). Journal of Cardiac Failure, 2013, 19, S69.	1.7	0
108	EFFECTS OF PATISIRAN, AN RNA INTERFERENCE THERAPEUTIC, ON REGIONAL LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: THE APOLLO STUDY. Journal of the American College of Cardiology, 2019, 73, 816.	2.8	0

#	Article	IF	Citations
109	Kardiale Beteiligung bei Amyloidose. Springer Reference Medizin, 2022, , 1-12.	0.0	0
110	A Consolidated Overview Of 14 Years Of Global Data From The Transthyretin Amyloidosis Outcomes Survey. Journal of Cardiac Failure, 2022, 28, S111.	1.7	0